Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus rating of “Buy” by the eight analysts that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $71.40.

Several brokerages recently commented on ARCT. Leerink Partners started coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective for the company. Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st.

Arcturus Therapeutics Trading Up 2.2 %

Arcturus Therapeutics stock opened at $18.74 on Tuesday. Arcturus Therapeutics has a 1-year low of $17.26 and a 1-year high of $45.00. The firm has a 50 day simple moving average of $20.64 and a 200 day simple moving average of $24.31.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The business had revenue of $49.86 million during the quarter, compared to analyst estimates of $21.00 million. During the same quarter in the previous year, the firm earned ($1.98) EPS. Analysts anticipate that Arcturus Therapeutics will post -2.6 earnings per share for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the transaction, the chief operating officer now directly owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 15.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently made changes to their positions in ARCT. Russell Investments Group Ltd. purchased a new position in Arcturus Therapeutics in the 1st quarter worth $40,000. nVerses Capital LLC purchased a new position in shares of Arcturus Therapeutics in the third quarter worth about $42,000. Quest Partners LLC lifted its stake in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 3,579 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 2,038 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Arcturus Therapeutics during the 2nd quarter worth approximately $142,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.